PharmaCyte Biotech (PMCB) Invested Capital (2016 - 2026)
PharmaCyte Biotech (PMCB) has disclosed Invested Capital for 15 consecutive years, with $35.2 million as the latest value for Q4 2025.
- On a quarterly basis, Invested Capital fell 18.91% to $35.2 million in Q4 2025 year-over-year; TTM through Oct 2025 was $35.2 million, a 18.91% decrease, with the full-year FY2025 number at $51.9 million, up 87.69% from a year prior.
- Invested Capital was $35.2 million for Q4 2025 at PharmaCyte Biotech, down from $43.6 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $92.1 million in Q4 2021 to a low of $5.7 million in Q3 2021.
- A 5-year average of $50.4 million and a median of $43.5 million in 2024 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: soared 1410.68% in 2022, then plummeted 61.97% in 2024.
- PharmaCyte Biotech's Invested Capital stood at $92.1 million in 2021, then dropped by 12.03% to $81.0 million in 2022, then plummeted by 54.63% to $36.8 million in 2023, then grew by 18.18% to $43.5 million in 2024, then decreased by 18.91% to $35.2 million in 2025.
- Per Business Quant, the three most recent readings for PMCB's Invested Capital are $35.2 million (Q4 2025), $43.6 million (Q3 2025), and $51.9 million (Q2 2025).